Navigation Links
Sequenom Addresses Preliminary Injunction Decision, Reaffirms Defense of Patent
Date:7/6/2012

SAN DIEGO, July 6, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today confirmed that the United States District Court for the Northern District of California  has denied  a motion by Sequenom for a preliminary injunction against Ariosa Diagnostics.  

"While obviously a disappointing preliminary outcome in our efforts to enforce an issued US patent against infringement, yesterday's decision is by no means a final ruling on the infringement or the validity of the '540 patent, but is one step in a long process to enforce our patent and protect our proprietary rights in the non-invasive prenatal testing marketplace," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc.

Earlier this year, Sequenom filed the motion against Ariosa (formerly Aria) Diagnostics to stop the company from making, using, selling or offering for sale, importing or exporting, infringing tests for detecting fetal chromosomal aneuploidy, such as Ariosa's Harmony Prenatal Test™, pending the ultimate resolution of the litigation.

Sequenom's request for preliminary injunctive relief followed its counterclaims filed in the lawsuit in the United States District Court for the Northern District of California, which allege that Ariosa is infringing U.S. Patent No. 6,258,540 ("'540 patent"). The case is ongoing and Sequenom will be seeking a full trial on the merits of its claims and all relief, including damages and a permanent injunction against Ariosa.

Using circulating cell free fetal nucleic acid as the analyte, as covered in the issued '540 patent, Sequenom Center for Molecular Medicine (Sequenom CMM) was the first fully certified clinical diagnostic laboratory to develop, fully validate in a major clinical study and bring to market a high precision non-invasive prenatal diagnos
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Sequenom to Host Analyst Day on Monday, November 14, 2011
3. Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
4. Sequenom Named to NASDAQ Global Select Market
5. Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook
6. Sequenom Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
7. Study In Prenatal Diagnosis Finds Sequenom CMMs MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets
8. Sequenom Announces Participation at the Jefferies Global Healthcare Conference
9. Sequenom Announces Appointment of Carolyn Beaver to Chief Accounting Officer
10. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
11. Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties Misleading Patent Assertions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 Immunovaccine Inc. ... immunotherapy company, today announced that the U.S. Food ... Fast Track designation and Phase I clinical trials ... with the mutual co-development agreement signed with Gilead ... Track designation for the DPX-Survivac. , “We have ...
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
(Date:2/26/2015)... N.J. , Feb. 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... trade secrets lawsuit against Genewiz Inc. in excess of ... and utilized GenScript,s trade secrets, and that it improperly ... entered an order denying motions for judgment notwithstanding the ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... of Chemistry Dunwei Wang has received a career award ... energy technology research and expand the community outreach programs ... on developing novel technologies for clean energy applications, has ... a flexible webbing of nano-scale wires that has shown ...
... N.C., Jan. 10, 2011 Takeda Pharmaceutical Company ... they have entered into an exclusive, worldwide licensing ... for the risk of Alzheimer,s disease in high-risk ... study pioglitazone in connection with the TOMM40 biomarker ...
... 10, 2011 Enobia Pharma Inc., today announced that ... ENB-0040, a bone targeted enzyme replacement therapy being investigated ... bone disorder. The results were presented by Robert Heft, ... the 29th Annual J.P. Morgan Healthcare Conference in San ...
Cached Biology Technology:Developer of 'nanonets' snares National Science Foundation Career Award 2Takeda and Zinfandel Pharmaceuticals Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... The global climate is changing, and this change is already ... affected by aridity need plants that can thrive / grow ... as milo, durra, or broomcorn, sorghum is a grass species ... is extremely resistant to aridity and hot conditions. The grass, ...
... the dangerous contaminants dry-cleaning fluids, solvents and petroleum ... the most urgent challenges facing environmental science. A report ... sheds light on a new way to monitor and ... developed at the University of Toronto. "The most ...
... particularly aggressive form of skin cancer malignant melanoma ... that diagnosis, might amplify the progression of their disease. ... also suggests that the use of commonly prescribed blood ... and therefore improve these patients, quality of life. ...
Cached Biology News:Genome of a heat and drought resistant cereal plant analyzed 2U of T technique put to use to test clean up of contaminated groundwater 2Stress may hasten the growth of melanoma tumors 2Stress may hasten the growth of melanoma tumors 3
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV ... be used in cDNA synthesis with long messenger ... of the pol gene of M-MLV and consists ... of 71kDa. The RNase H activity of M-MLV ...
... 8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) ... 8-isoprostane (8-iso PGF2α), in rabbits, monkeys ... PG-like product of non-specific lipid peroxidation. ... infused 8-isoprostane is converted primarily to ...
... Cell Cultures (ECACC) in conjunction with the ... of England, Bristol, UK, have produced standardised ... HER2, oestrogen and progresterone receptor assays. The ... formalin fixed, breast cancer cell lines; MDA-MD-361, ...
Biology Products: